Are you at risk to develop pancreatic cancer ?

1. AGE

Pancreatic cancer only rarely occurs in people under 45. Most people who are diagnosed with pancreatic cancer are over the age of 60


People with diabetes are more likely to be at risk, and especially people over 50 with new onset diabetes (Type 2 Diabetes) or people who have long-standing diabetes who experience a sudden shift in insulin levels.


People with family members who had pancreatic or other cancer may be more at risk. Up to 10% of all pancreatic cancer cases are the result of inherited genetic variants. An Inherited Cancer Genetic Risk Test is recommended to assess an individual’s risk for inherited cancer (including pancreatic cancer).


People with pancreatitis, which is inflammation of the pancreas, have an elevated risk to develop pancreatic cancer. Chronic pancreatitis is associated with heavy alcohol use and smoking.


A higher body-mass index is associated with an increased chance of being diagnosed with pancreatic cancer. Obesity can increase pancreatic cancer risk by up to 20%.


Studies estimating that smokers may be 2x more likely to develop pancreatic cancer than non-smokers. Other factors may include excessive alcohol consumption, processed meats, unhealthy fats, and too much sugar.


African-Americans and people of Ashkenazi Jewish descent seem to have a slightly higher risk of developing pancreatic cancer.


Exposure to industrial chemicals including pesticides, asbestos, benzene, heavy metals, and chlorinated hydrocarbons which includes PCBs and DDT are just some of the toxic chemicals that have been linked to pancreatic cancer.


Many sources also list people with gum disease and/or tooth loss (periodontal disease) as another group who may be at an elevated risk to develop pancreatic cancer.

The BT-Reveal Early Pancreatic Cancer Test is exclusively available through
BREAKTHROUGH GENOMICS. The company provides genetic tests for rare disease
diagnosis and early cancer detection at its CAP and CLIA-certified,
advanced clinical lab in Southern California.

If you have questions or would like more information please email us:

Technology Partner:


The BT-Reveal Early Pancreatic Cancer Test is intended for use as a screening tool for at-risk individuals. A positive result does not guarantee the individual has cancer. For all positive results, additional follow-up imaging and other confirmatory tests are recommended. Common follow up testing includes CT Scans, MRI’s, Endoscopic Ultrasounds, or ERCP tests.

Breakthrough Genomics’s clinical laboratory in Irvine, California is certified in the U.S. under the Clinical Laboratory Improvements Amendments (CLIA) and by the College of American Pathologists (CAP) to perform high complexity clinical genomic tests. The BT-Reveal Early Pancreatic Cancer Test only requires a 10ml tube of blood that can be stored and transported at room temperature. The test is currently being offered as a Laboratory Developed Test (LDT) and as such surpasses the lab’s requirements needed to be able to safely provide the test to at-risk individuals.

Screenshot 2023-09-25 170444

2 Hughes #100, Irvine, CA 92618

Breakthrough Genomics